metaPreg - Triazolam during pregnancy

Triazolam updated on 02-10-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	0.91 [0.72, 1.16]	-	1 study	156,966	1,299	not evaluable	ROB	-
Congenital heart defects	1.12 [0.83, 1.51]	-	1 study	83,629	1,299	not evaluable	ROB	-
Major congenital malformations	0.91 [0.72, 1.16]	-	1 study	156,966	1,299	not evaluable	ROB	-
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	1.37 [1.10, 1.71]	-	1 study	250,892	742	not evaluable	ROB	2.08 [1.43; .]
Small for gestational age (weight)	1.22 [0.98, 1.52]	-	1 study	266,254	749	not evaluable	ROB	-
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Late intrauterine deaths (> 22 weeks) / Stillbirths	0.87 [0.43, 1.76]	-	1 study	32,331	750	not evaluable	ROB	-
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions	1.14 [0.11, 11.82]	-	1 study	27,149	5	not evaluable	ROB	-
Hide endpoints reported in only one study ...